Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Indeed, despite the cheerleaders' attempts to entice people to buy the stock!
And what have been the opportunity costs of being in PMCB for a long time?
Answer: missed BIG gains in the market, as all indices have skyrocketed over the past several years.
People who have been long in PMCB have lost a lot so far in relation to the rest of the market.
It MIGHT have made sense to cash in some profits made in the market over the past few years to take a flyer on PMCB at a nickel a share in October 2017. But being long in this stock has been a very unprofitable (losing) venture.
It's not exactly encouraging if their story is complete before an IND and clinical trial. Scam!
This is what I've been saying for the past year--immunotherapy and targeted therapy is the way forward.
That was a contest with votes coming from shareholders, not scientists.
Fitting that the award is a scam, just like the company.
Afraid of things that don't exist.
Like an IND and a clinical trial?
Sounds about right.
Here we are, in the 4th quarter of 2017, and..........nothing!
PMCB is falling toward the .04s; good luck to everybody who has invested.
**I of course meant "fire."**
Biotech is on fir today. I hope that everybody is profiting!
CAR T is hogging the headlines because it has been proven in clinical trials to extend life by years in some patients.
PMCB can't even conduct a clinical trial of its ancient off-patent technology.
CAR T cells are life saving for patients who have exhausted most other treatments. Right now they're being used for hematologic cancer. Side effects include cytokine release syndrome, which can be serious if not managed quickly and aggressively. It is indeed breakthrough as oncologists will tell you. I invested in 3 of theCAR T cell players, one of which has more than quadrupled in value and was just bought out by Gilead.
Answer: That technology is currently worth 6 cents per share.
You'll note that big biotech is willing to shell out billions for companies with proven technologies. Not so much for companies with old technologies that are off patent and haven't proven a thing.
If you could go back and look at this message board 1 year ago, it would look hauntingly similar to the way it does today, with the longs holding onto the future promises made by PMCB with no concrete timelines, and the naysayers pointing out the all of the broken promises.
The mythical clinical trial is always tantalizingly close to hold the interest of the longs. It's just around the corner...2 or 3 quarters from now. Six months later, it's still 2 or 3 quarters in the future.
Meanwhile, CAR-T cells are on the verge of approval after less time in the lab. And PMCB can't even get a clinical trial off the ground.
Are you sure this PR wasn't produced by a satire site? It's hilarious!
This PR will be celebrating its fourth anniversary very soon!
Thank you for this dose of rationality.
But if they actually followed through with a clinical trial and it fails, then their scam will be up!
They must always hold that carrot (clinical trial) out to seduce the investors.
As an ASCO attendee for the past decade, I can assure you that there is more to ASCO than presenting clinical trial results. There are state-of-the-art lectures, basic science lectures, review presentations, presentations on mechanisms of action, pipeline candidates and posters on clinical trials in progress. There are also subanalyses and post hoc analyses of clinical trials presented previously.
We'll see how much mileage they get from today's pump.
Actually, the drugs approved for treating acid reflux work on histamine receptors or proton pumps.
Directing treatment directly at the tumor is fine but it does nothing to interfere with activation of the molecular pathway that caused the tumor to begin with not does it treat metastases.
It's difficult enough to read KW's BS once let alone review it.
And I'll go with the stated definition of targeted therapy as established by basic research scientists and oncologists. Targeting a tumor is far different from targeting a molecular pathway.
Read the link I posted before. The term "targeted" has a specific meaning in oncology and it's not chemotherapy delivered by cell-in-a box. I have attended hundreds of oncology lectures over the past decade and never have I heard targeted therapy defined as any type of localized chemotherapy, which CIAB is.
As this link states, chemotherapy interferes with cell division and thus is not targeted. Targeted, or molecular therapies, inhibit molecular pathways.
https://www.mycancergenome.org/content/molecular-medicine/overview-of-targeted-therapies-for-cancer/
Wrong. Chemotherapy is not targeted therapy per the oncology definition. Cell in a box would do nothing for metastatic disease, whereas targeted therapies will have an effect regardless of the primary or metastatic site of the tumor.
The true value is that established by the market. Six cents. If you personally won't sell at under $1.00, you're going to have to hope that the market eventually says that the shares are worth $1.00.
It's not his opinion, it's a fact that the market values the company at about 6 cents per share.
This is definitely NOT a targeted therapy. A targeted therapy looks for activation pathways to interrupt them, usually based on a driver mutation or a resistance mutation.
The technology is questionable. There's absolutely no buzz about it amongst oncologists. The field has advanced to immunotherapy and targeted therapies.
...then you missed out on the surge in biotech this week. Gains of 15% to 20%.
Biotech is having an insanely profitable week with lots of run-ups. I hope that everybody here was able to take advantage.
It's the old fourth quarter trick. Keep dangling a vague time in the not-too-distant future for the mythical clinical trial to keep shareholders hanging on! Ha!
That stop will occur when shen shareholders wise up and pull out.
You're giving the benefit of doubt to a company that has never proven that it can follow through on what it proposes. That trust is not earned, and while delay after delay hinders PMCB, other strategies (ie, immunotherapy) to treat pancreatic cancer are moving forward. Even if the mythical clinical trial is ever approved, the technology could be obsolete for pancreatic cancer by the time it's finished.
A good history lesson for the excuse makers!
That mythical clinical trial has been promised for more than 2 years.
"Although the details were not provided (which angers me as well) I'm sure the updates were positive."
I'm just as certain that they were negative. Otherwise, we would be reading positive news.
Amazing that they fashioned a PR about a non-event such as this, while real companies were making big news inside the McCormick Convention Center in Chicago.
After attending ASCO, I'm convinced that immunotherapy is the way forward for pancreatic cancer. The right combination of strategies to target T regulatory cells while adding a vaccine, or some combination of checkpoint inhibitors and agents to boost tumor-infiltrating lymphocytes will be the way to go. This approach is being tested in several difficult-to-treat cancers like ovarian cancer. Chemotherapy may play a role in enhancing immunotherapy response but PMCB likely missed its window as a treatment after gemcitabine failure, which was probably 5 years ago. Still waiting for an announcement of the start of the mythical clinical trial.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330603/